Academia Urges More Transparency on Labels - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Academia Urges More Transparency on Labels

ePT--the Electronic Newsletter of Pharmaceutical Technology

Researchers from the Stanford University School of Medicine in California are urging the US Food and Drug Administration to demand that drug manufacturers state how new medications compare with similar treatments on product labels. "In many instances, these statements would indicate that there is no evidence that a new drug is more effective than older ones," according to a Stanford news release.

Stafford and his fellow researchers published an essay on the subject in the New England Journal of Medicine. They recommend that FDA require new drugs to carry a label that says, for example: "Although this drug has been shown to lower blood pressure more effectively than placebo, it has not been shown to be more effective than other members of the same drug class." The researchers believe that "developing more informative labels is consistent with the agency's recently invigorated function as a public health agency." (see back story, A Fresh Perspective at FDA.)

The researchers believe that making such information available may influence the decisions made by patients and healthcare insurers. New drugs are often more expensive than existing therapies and may be no more effective. "The public's appetite for the latest drugs might be curbed if patients understood that new treatments aren't necessarily more effective than existing ones," explained the news release.

"Drug and device manufacturers benefit from an unacknowledged information gap that develops as more and more products are tested against placebo, but not each other," said Randell Stafford, associate professor of medicine at the Stanford Prevention Research Center, in the release.

Stephanie Sutton is an assistant editor with PharmTech Europe.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here